OncoMatch/Clinical Trials/NCT07254585
SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma
Is NCT07254585 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including SYS6010 and Enlonstobart for head and neck squamous cell carcinoma.
Treatment: SYS6010 · Enlonstobart — This study is a n open-label, multi-center, phase II study to evaluate the efficacy and safety of SYS6010 combined with Enlonstobart in the recurrent or metastatic head and neck squamous cell carcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) positive (CPS≥1) (CPS≥1)
baseline PD-L1 positivity (CPS≥1) must be confirmed by the central laboratory; for participants who have previously received systemic antitumor treatment, there is no restriction on baseline PD-L1 expression
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
Major organ function must meet the criteria within 7 days prior to the first dose of the study intervention
Kidney function
Major organ function must meet the criteria within 7 days prior to the first dose of the study intervention
Liver function
Major organ function must meet the criteria within 7 days prior to the first dose of the study intervention
Major organ function must meet the criteria within 7 days prior to the first dose of the study intervention
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify